Monte Rosa Therapeutics Collaborates with Novartis

By Greg Peters • Monday, September 15 15:30 • Permanent Link

Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE) has announced a collaboration with Novartis to develop novel degraders for immune-mediated diseases. This is the second agreement between the two companies, following the global exclusive license agreement for Monte Rosa's vav1 degraders including MRT-6160, announced in October 2024.

Under the terms of the new agreement, Monte Rosa will receive an upfront payment of $120 million. Additionally, the company is eligible to receive up to $5.7 billion in total deal value, including various milestone payments and tiered royalties on global net sales in the high single to low double-digit range.

The collaboration with Novartis provides Monte Rosa with an extended cash runway, enabling the company to accelerate its preclinical and clinical-stage immunology & inflammation (I&I) pipeline. This includes progressing wholly owned programs, such as multiple undisclosed targets in th1, th2, and th17-driven autoimmune conditions.

Monte Rosa's AI/ML-enabled Queen™ product engine continues to generate new insights and opportunities, delivering an expanding pipeline of programs directed against historically undruggable immunology targets.

Fiona Marshall, Ph.D., President of Biomedical Research at Novartis, expressed the company's commitment to advancing targeted protein degradation as a promising approach to address immune-mediated diseases with high unmet need. Novartis believes that Monte Rosa's Queen™ platform has the potential to uncover new insights in this field and looks forward to working together to translate these insights into transformative therapies for patients.

Monte Rosa plans to provide further information regarding its updated cash position and runway in its third-quarter 2025 earnings update.

Monte Rosa Therapeutics is a clinical-stage biotechnology company developing highly selective molecular glue degrader (MGD) medicines for patients living with serious diseases in the areas of oncology, autoimmune and inflammatory diseases. The company's Queen™ discovery engine combines AI-guided chemistry, diverse chemical libraries, structural biology, and proteomics to rationally design MGDs with unprecedented selectivity. Monte Rosa has developed a leading pipeline of MGDs, spanning autoimmune and inflammatory diseases, oncology, and beyond. The market has reacted to these announcements by moving the company's shares 42.03% to a price of $6.8318. For the full picture, make sure to review Monte Rosa Therapeutics's 8-K report.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.